Metabolic actions of fibroblast growth factor 21

Current Opinion in Pediatrics

Volumn 24, Issue 4, 2012, Pages 523-529

  Cuevas Ramos, Daniel ^a   Aguilar Salinas, Carlos A ^a   Gómez Pérez, Francisco J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

fibroblast growth factor 21; glucose; lipid metabolism; liver steatosis; obesity

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; FIBROBLAST GROWTH FACTOR 21; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RECOMBINANT FIBROBLAST GROWTH FACTOR 21; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG;

ADIPOGENESIS; ADIPOSE TISSUE; APPETITE; AUTOCRINE EFFECT; DRUG ACTIVITY; DRUG MECHANISM; DYSLIPIDEMIA; FATTY LIVER; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; KETOGENESIS; LIPID METABOLISM; LIPOTOXICITY; LIVER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATION; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; STARVATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; LIVER; MALE; MICE; MICE, OBESE; PPAR GAMMA;

EID: 84863814092     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3283557d22     Document Type: Review

References (63)

1. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochem Biophys Acta 2000; 203-206.
2. Izumiya Y, Bina HA, Ouchi N, et al. FGF21 is an AKT-regulated miokine. FEBS Lett 2008; 582:3805-3810.
3. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor 21 improves pancreatic b-cell function and survival by activation of extracellular signalregulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55:2470-2478.
4. Zhang X, Yeung DCY, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57:1246-1253.
5. Uebanso T, Taketani Y, Tamamoto H, et al. Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor? PLoS One 2011; 6:e22976.
6. Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 2011; 149:121-130.
7. Kurosu H, Kuro OM. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009; 299:72-78.
8. Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 2007; 104:7432-7437.
9. Yie J, Hecht R, Patel J, et al. FGF21 N-and C-termini play different roles in receptor interaction and activation. FEBS Lett 2009; 583:19-24.
10. Dickinson CD, Kharitonenkov A. Different roles of N-and C-termini in the functional activity of FGF21. J Cell Physiol 2009; 219:227-234.
11. Fon Tacer K, Bookout AL, Ding X, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010; 24:2050-2064.
12. Yie J, Wang W, Deng L, et al. Understanding the physical interactions in the FGF21/FGFR/b-Klotho complex: structural requirements and implications in FGF21 signaling. Chem Biol Drug Des 2012; 79:398-410.
13. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPAR-alfa mediated induction of FGF21. Cell Metab 2007; 5:415-425.
14. Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 2008; 74:403-412.
15. Wang H, Qiang L, Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 2008; 28:188-200.
16. Qiang L, Accili D. FGF21 and the second coming of PPARg. Cell 2012; 148:397-398.
17. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115:1627-1635.
18. Moyers JS, Shiyanova TL, Mehrbod F, et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 2007; 2010:1-6.
19. Dutchak P, Katafuchi T, Bookout AL, et al. Fibroblast growth factor-21 regulates PPARg activity and the antidiabetic actions of thiazolidinediones. Cell 2012; 148:556-567.
20. Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPAR-alfa and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5:426-437.
21. Gälman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARa activation in man. Cell Metab 2008; 8:169-174.
22. Ludansen T, Hunt MC, Nilsson LM, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007; 360:437-440.
23. Mai K, Andres J, Biedasek K, et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor 21. Diabetes 2009; 58:1532-1538.
24. Li H, Gao Z, Zhang J, et al. Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes 2012; 61:797-806.
25. De Sousa-Coelho AL, Marrero PF, Haro D. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J 2012; 443:165-171.
26. Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 2009; 106:10853-10858.
27. Matikainen N, Taskinen MR, Stennabb S, et al. Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. Eur J Endocirnol 2012; 166:487-492.
28. Inagaki T, Lin VY, Goetz R, et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008; 8:77-83.
29. Yu J, Zhao L, Wang A, et al. Growth hormone stimulates transcription of the fibroblast growth factor 21 gene in the liver through the signal transducer and activator of transcription 5. Endocrinology 2012; 153:750-758.
30. Kunicky RA, Wu S, Kharitonenkov A, De Luca F. Role of fibroblast growth factor 21 (FGF21) in under nutrition-related attenuation of growth in mice. Endocrinology 2012; 153:2287-2295.
31. Fisher M, Kleiner S, Douris N, et al. FGF21 regulates PGC-1a and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012; 26:271-281.
32. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149:6018-6027.
33. Tan BK, Halschmid M, Adya R, et al. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid. Diabetes 2011; 60:2758-2762.
34. Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010; 59:1817-1824.
35. Christodoulides C, Dyson P, Sprecher D, et al. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 2009; 94:3594-3601.
36. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139:456-463.
37. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008; 93:3627-3632.
38. Schoenberg KM, Giesy SL, Harvatine KJ, et al. PlasmaFGF21 is elevated by the intense lipid mobilization of lactation. Endocrinology 2011; 152:4652-4561.
39. Chen W, Hoo RL, Konishi M, et al. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem 2011; 286:34559-34566.
40. Cuevas-Ramos D, Almeda-Valdés P, Gómez-Pérez FJ, et al. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 2010; 163:469-477.
41. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 20: from feast to famine. Genes Dev 2012; 26:312-324.
42. Arner P, Pettersson A, Mitchell PJ, et al. FGF21 attenuates lipolysis in human adipocytes: a possible link to improved insulin sensitivity. FEBS Lett 2008; 582:1725-1730.
43. Chen WW, Li L, Yang GY, et al. Circulating FGF21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116:65-68.
44. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32:1542-1546.
45. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010; 53:934-940.
46. Li X, Fan X, Ren F, et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract 2011; 93:10-16.
47. Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010; 40:887-892.
48. An SY, Lee MS, Yi SA, et al. Serum fibroblast factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 2012; 96:196-203.
49. Yang SJ, Hong HC, Choi HY, et al. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol 2011; 75:464-469.
50. Thi HD, Tselykh TV, Mä kelä J, et al. Fibroblast growth factor 21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/mylip-interacting saposin-like protein (MSAP). J Biol Chem 2012; 287:12602-12611.
51. Reinehr T, Woelfle J, Wunsch R, et al. Fibroblast growth factor 21 (FGF21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 2012
52. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59:2781-2789.
53. Hale C, Chen MM, Stanislaus S, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2011; 153:69-80.
54. Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and g-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94:2151-2156.
55. Hojman P, Pedersen M, Nielsen AR, et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009; 58:2797-2801.
56. Samba R, Sun K, Egan JM, et al. Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: The Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2012; 97:1375-1382.
57. Stein S, Bachmann A, Lö ssner U. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 2009; 32:126-128.
58. Yu H, Xia F, Lam KSL, et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 2011; 57:691-700.
59. Andersen B, Beck-Nielsen H, Hojlund K. Plasma FGF21 displays a circadian rhythm, during 72-h fast in healthy female volunteers. Clin Endocrinol 2011; 75:514-519.
60. Lee SA, Jeong E, Kim EH, et al. Various oscillation patterns of serum fibroblast growth 21 concentrations in healthy volunteers. Diabetes Metab J 2012; 36:29-36.
61. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58:250-259.
62. Wu AL, Kolumam G, Stawicki S, et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med 2011; 3:113ra126.
63. Wei W, Dutchak PA, Wang X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of PPARg. Proc Natl Acad Sci U S A 2012; 109:3143-3148.